John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
Investigators used next-generation sequencing to characterize the genomic profile of squamous cell carcinoma (SCC) in 26 Colombian patients with lung SCC.
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
The MET alteration occurs in 3% to 4% of patients with the condition.
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
The treatment reduced hospital stay but not neutropenia duration or infection rate.
The increase is thought to be related to environmental factors.
Combining 2 predictors yielded better results than just using 1.
